



## **Amgen Names Joshua Ofman Vice President, Reimbursement and Payment Policy**

July 1, 2004

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 1, 2004--Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology company, today announced the appointment of Joshua Ofman, M.D., M.S.H.S., to the new position of vice president, Reimbursement and Payment Policy. As of today, Ofman will be responsible for the design and execution of Amgen's reimbursement and payment strategy and will help to ensure the integration of reimbursement needs into the product development and commercialization process.

"Josh is an acknowledged physician expert in health economics and a respected member of the health care policy world," said David Beier, Amgen's senior vice president, Global Government Affairs. "In this new role, Josh is leading the effort to ensure that patients have access to Amgen's products and that payors, especially governments, understand the value proposition that our products represent."

Ofman joined Amgen in 2003 as senior director, U.S. Medical Affairs, and head of Amgen's U.S. Health Economics and Outcomes Research group. Prior to joining Amgen, Ofman was an academic gastroenterologist at Cedars-Sinai Health System and senior vice president of Zynx Health, Inc., a subsidiary of Cerner Corp., a publicly traded healthcare information technology company. Ofman obtained his undergraduate degree from the University of California at Berkeley and his M.D. from the University of California, Irvine College of Medicine. He conducted his internship and residency in internal medicine, and fellowship in digestive diseases at the University of California, Los Angeles (UCLA) Department of Medicine. In addition, Ofman completed a RAND/VA/UCLA fellowship in ambulatory care and health services research, specializing in technology assessment, and received a Masters of Science in Health Services from the UCLA School of Public Health.

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology and medicinal chemistry.

CONTACT: Amgen  
Mary Klem, 805-447-4587 (media)

SOURCE: Amgen Inc.